摘要
目的检测多发性骨髓瘤治疗前及治疗后血清中DKK1的表达水平,分析其临床意义及与治疗的相关性。方法通过ELISA法检测25例多发性骨髓瘤患者治疗前及治疗后血清中DKK1的表达水平,并以23例健康成年人为对照组。结果①Ⅱ/Ⅲ期初治多发性骨髓瘤患者血清DKK1水平高于I期患者[(13.26±11.85)ng/mLVS(3.03±0.93)ng/mL]](P=0.011),并高于健康对照组[(2.83±1.75)ng/mL](P<0.001)。②治疗有效者治疗后血清DKK1水平较治疗前显著降低[(12.93±11.22)ng/mLVS(7.01±3.14)ng/mL,P<0.001],在传统治疗组及新药治疗组均有显著差异(P分别为0.018,0.028)。③难治复发多发性骨髓瘤患者血浆DKK1水平治疗前后无显著差异[(7.57±6.38)ng/mLv(s6.98±4.60)ng/mL,P=0.441]。结论多发性骨髓瘤DKK1表达水平增加并与疾病分期有关,疾病缓解后DKK1水平下降。
Objective To detect serum concentrations of Dickkopf1 （DKK1） in patients with multiple myeloma （MM） before and after treatment, and to investigate its clinical significance. Methods Serum DKK1 levels were quantified in 25 MM patients before and after treatment with ELISA . Results ① Serum DKK1 levels of myeloma patients were correlated with Durie and Salmon stages [（3.03±0.93）ng/mL of stage I with compared （13.26±11.85）ng/mL of stage II/III, P=0.002], and is higher than that of health control[（2.83±1.75）ng/mL] （P0.001）. ②Myeloma patients who responded to the treatment had significantly lower DKK1 levels post-treatment [（7.01±3.14）ng/mL with compared（12.93±11.22）ng/mL, P0.001]. ③Myeloma patients who was refractory to the treatment or relapsed after treatment had no significantly lower DKK1 levels post-treatment [（6.98±4.60）ng/mL with compared（7.57±6.38）ng/mL, P=0.441]. Conclusion Myeloma patients have increased serum DKK1 which have close relationship with myeloma stage. After remission the level of serum DKK1 decreased.
出处
《中国医药指南》
2010年第13期181-182,201,共3页
Guide of China Medicine
